Page 53 - Read Online

Page 14 of 15 Dasgupta et al. J Transl Genet Genom 2018;2:15. I https://doi.org/10.20517/jtgg.2018.21

REFERENCES
1. Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, et al. Global incidence of malignant brain and other central nervous system tumors by
histology, 2003-2007. Neuro Oncol 2017;19:1553-64.
2. Khanna V, Achey RL, Ostrom QT, Block-Beach H, Kruchko C, et al. Incidence and survival trends for medulloblastomas in the United
States from 2001 to 2013. J Neurooncol 2017;135:433-41.
3. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, et al. Molecular subgroups of medulloblastoma: an international meta-
analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, group 3, and group 4 medulloblastomas. Acta Neuropathol
2012;123:473-84.
4. Gajjar A, Bowers DC, Karajannis MA, Leary S, Witt H, et al. Pediatric brain tumors: innovative genomic information is transforming the
diagnostic and clinical landscape. J Clin Oncol 2015;33:2986-98.
5. Gupta T, Shirsat N, Jalali R. Molecular subgrouping of medulloblastoma: impact upon research and clinical practice. Curr Pediatr Rev
2015;11:106-19.
6. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta
Neuropathol 2012;123:465-72.
7. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, et al. The 2016 World Health Organization classification of
tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803-20.
8. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, et al. Medulloblastoma comprises four distinct molecular variants. J Clin
Oncol 2011;29:1408-14.
9. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic
profiles, pathway signatures and clinicopathological features. PLoS One 2008;3:e3088.
10. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, et al. Integrative genomic analysis of medulloblastoma identifies a molecular
subgroup that drives poor clinical outcome. J Clin Oncol 2011;29:1424-30.
11. Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, et al. Real-time PCR assay based on the differential expression of microRNAs and
protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol 2013;15:1644-51.
12. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, et al. Definition of disease-risk stratification groups in childhood medulloblastoma
using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011;29:1400-7.
13. Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, et al. Integrating molecular subclassification of medulloblastomas into routine clinical
practice: a simplified approach. Brain Pathol 2016;26:334-43.
14. Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, et al. DNA methylation profiling of medulloblastoma allows robust
subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol 2013;125:359-71.
15. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, et al. Robust molecular subgrouping and copy-number profiling of
medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol
2013;125:913-6.
16. Koeller KK, Rushing EJ. From the archives of the AFIP: medulloblastoma: a comprehensive review with radiologic-pathologic correlation.
Radiographics 2003;23:1613-37.
17. Gupta T, Sarkar C, Rajshekhar V, Chatterjee S, Shirsat N, et al. Indian society of neuro-oncology consensus guidelines for the contemporary
management of medulloblastoma. Neurol India 2017;65:315-32.
18. Kuo MD, Jamshidi N. Behind the numbers: decoding molecular phenotypes with radiogenomics--guiding principles and technical
considerations. Radiology 2014;270:320-5.
19. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.
20. Kickingereder P, Andronesi OC. Radiomics, metabolic, and molecular MRI for brain tumors. Semin Neurol 2018;38:32-40.
21. Teo WY, Shen J, Su JM, Yu A, Wang J, et al. Implications of tumor location on subtypes of medulloblastoma. Pediatr Blood Cancer
2013;60:1408-10.
22. Perreault S, Ramaswamy V, Achrol AS, Chao K, Liu TT, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J
Neuroradiol 2014;35:1263-9.
23. Wefers AK, Warmuth-Metz M, Poschl J, von Bueren AO, Monoranu CM, et al. Subgroup-specific localization of human medulloblastoma
based on pre-operative MRI. Acta Neuropathol 2014;127:931-3.
24. Lastowska M, Jurkiewicz E, Trubicka J, Daszkiewicz P, Drogosiewicz M, et al. Contrast enhancement pattern predicts poor survival for
patients with non-WNT/SHH medulloblastoma tumours. J Neurooncol 2015;123:65-73.
25. Bluml S, Margol AS, Sposto R, Kennedy RJ, Robison NJ, et al. Molecular subgroups of medulloblastoma identification using noninvasive
magnetic resonance spectroscopy. Neuro Oncol 2016;18:126-31.
26. Patay Z, DeSain LA, Hwang SN, Coan A, Li Y, et al. MR imaging characteristics of wingless-type-subgroup pediatric medulloblastoma.
AJNR Am J Neuroradiol 2015;36:2386-93.
27. Keil VC, Warmuth-Metz M, Reh C, Enkirch SJ, Reinert C, et al. Imaging biomarkers for adult medulloblastomas: genetic entities may be
identified by their MR imaging radiophenotype. AJNR Am J Neuroradiol 2017;38:1892-8.
28. Zhao F, Li C, Zhou Q, Qu P, Wang B, et al. Distinctive localization and MRI features correlate of molecular subgroups in adult
medulloblastoma. J Neurooncol 2017;135:353-60.
29. Mata-Mbemba D, Zapotocky M, Laughlin S, Taylor MD, Ramaswamy V, et al. MRI characteristics of primary tumors and metastatic
lesions in molecular subgroups of pediatric medulloblastoma: a single-center study. AJNR Am J Neuroradiol 2018;39:949-55.
30. Zapotocky M, Mata-Mbemba D, Sumerauer D, Liby P, Lassaletta A, et al. Differential patterns of metastatic dissemination across